The present disclosure discloses use of scutellarin in a medicament and a modulator for preventing or treating diseases, a medicament, and a modulator, which is related to the technical field of medicine. The present disclosure discloses use of scutellarin in the preparation of a medicament for preventing or treating a disease caused or mediated by interaction between TNF and TNFR2. The research in the present disclosure has shown that scutellarin is capable of selectively inhibiting TNF-induced death of WEHI-13VAR cells and significantly inhibiting TNF-induced proliferation of Tregs, accompanied with down-regulation of TNFR2 and Foxp3 expression in Tregs. This indicates that scutellarin can be used to treat or prevent relevant diseases caused or mediated by the interaction between TNF and TNFR2, and the present disclosure provides a new idea or means for preventing or treating relevant diseases caused or mediated by the interaction between TNF and TNFR2.